financetom
Business
financetom
/
Business
/
Update: US FTC Report Says Pharmacy Benefit Managers Contribute to Higher Drug Costs
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: US FTC Report Says Pharmacy Benefit Managers Contribute to Higher Drug Costs
Jul 10, 2024 4:22 AM

07:06 AM EDT, 07/10/2024 (MT Newswires) -- (Updates to add comment from United Health's Optum in the seventh paragraph.)

CVS Health's ( CVS ) Caremark, UnitedHealth Group's ( UNH ) Optum, and Cigna Group's ( CI ) Express Scripts are among the top six pharmacy middlemen that contribute to higher drug costs and challenge the viability of independent pharmacies, the US Federal Trade Commission said Tuesday in an interim report on pharmacy benefit managers.

Pharmacy benefit managers act as intermediaries in the pharmaceutical supply chain, negotiating drug prices and access for hundreds of millions of Americans with the top three PBMs -- Caremark, Optum, and Express Scripts -- managing 79% of prescription drug claims for 270 million people, the FTC said in its 71-page report.

The combined revenue of UnitedHealth ( UNH ), CVS Health ( CVS ), Cigna Group ( CI ), and Humana totaled $456 billion in 2016 and equaled 14% of US health expenditures, the report said. "Today, their combined revenue exceeds $1 trillion and equals 22% of national health expenditures."

PBMs have expanded into health insurers, healthcare providers, and drug private labeling, further increasing their influence and control over the healthcare market, the report said.

FTC Commissioner Melissa Holyoak issued a dissenting statement and said the report "leaves us without a better understanding of the competition concerns surrounding PBMs or how consumers are impacted by PBM practices."

"Our efforts have resulted in members on average paying less than $8 per 30-day supply of medication," CVS Caremark said in an email to MT Newswires. Any FTC policies limiting PBM negotiation tools would favor pharmaceutical companies and harm consumers, the company added.

"PBMs, like Optum Rx, are the key counterweight to pharmaceutical companies' monopoly power to set and raise drug prices," Optum Rx said in response to a request for comment from MT Newswires. "The FTC has rushed to publish an incomplete report with flawed conclusions that do not follow from the data and information Optum Rx provided to the agency," Optum added.

Cigna ( CI ) and Humana didn't immediately respond to requests for comment from MT Newswires.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
SJVN secures 200-MW wind power project at ₹3.24 per unit
SJVN secures 200-MW wind power project at ₹3.24 per unit
Nov 16, 2023
Projected to generate 482 million units in its inaugural year post-commissioning, the cumulative energy generation over a 25-year span is anticipated to reach 12,050 million units. Shares of SJVN Ltd ended at ₹75.17, down by ₹0.50, or 0.66%, on the BSE.
Suzlon's S144–3 MW wind turbines get big boost from Indian government
Suzlon's S144–3 MW wind turbines get big boost from Indian government
Nov 15, 2023
Th Suzlon wind turbines received the RLMM (Revised List of Models & Manufacturers) listing from the Ministry of New and Renewable Energy, marking an important milestone for the successful commercialisation of the product. Shares of Suzlon Energy Ltd ended at ₹40.49, up by ₹1.85, or 4.79%, on the BSE.
This sustainable jewellery brand is luring some women away from gold
This sustainable jewellery brand is luring some women away from gold
Oct 30, 2023
Aulerth's offerings range from ₹5,000 to as high as ₹2.8 lakh. Are women willing to spend this much on jewellery made from scrap? Founder and CEO Vivek Ramabhadran definitely believes so. Aulerth produces couture-inspired pieces in association with designers like JJ Valaya, Suneet Varma, among others. It has reported 33% repeat customers in the past year and expects a spike to 40% soon.
Tata Power Renewable Energy wins 200-MW project in collaboration with SJVN
Tata Power Renewable Energy wins 200-MW project in collaboration with SJVN
Nov 28, 2023
The firm and dispatchable renewable energy (FDRE) project, designed with a hybrid of solar, wind, and battery storage, is aimed at providing a stable and dispatchable energy supply during peak hours. Shares of Tata Power Company Ltd ended at ₹270.75, up by ₹12.60, or 4.88%, on the BSE.
Copyright 2023-2026 - www.financetom.com All Rights Reserved